摘要
目的：通过伊日沙坦（国产）与缬沙坦（合资）的对比研究来评价伊贝沙坦对轻、中度原发性高血压的降压疗效和安全性。 方法：５３例轻、中度原发性高血压患者被随机、双盲分为两组，经口服安慰剂２周后，分别每日口服１次伊贝沙坦７５～１５０ ｍｇ（伊贝沙坦组）或缬沙坦８０～１６０ ｍｇ（缬沙坦组），治疗４周，观察用药前后坐位血压、心率变化，对比用药前后血生化、血尿常规检查结果，记录患者用药后的不良反应。 结果：治疗４周后，伊贝沙坦组舒张压降低 １３．３±８．７ ｍｍＨｇ（ｌｍｍＨｇ＝０．１３３ ｋＰａ）缬沙坦组舒张压降低 １６．５±９． ３ ｍｍＨｇ。两组治疗后与治疗前相比，血压下降有非常显著差异（Ｐ＜０．０１），心率变化、血生化及血尿常规检查结果比较无显著差异（Ｐ＞０．０５）。总有效率及不良反应发生出率两组间比较均无显著差异（Ｐ＞０．０５）。 结论：口服伊贝沙坦 ７５～１５０ ｍｇ，每日１次，对轻、中度原发性高血压降压疗效确切，患者耐受性好。
Objectives: To compare the antihypertensive effect and safety of irbesatan and valsartan. The efficacy and tolerability of irbesartan was evaluated. Methods:Fifty-three patients with mild to moderate hypertension were randomly divided into two groups in doubleblind manner. One group was treated with irbesartan 75～150 mg/d(irbesartan group),the other group with valsartan 80 ～60 mg/d(valsartan group),for 4 weeks. Sitting blood pressure,heart rate and laboratory examination of the patients were observed at baseline and post-treatment. Adverse reactions were recorded. Results:Diastolic blood pressure was reduced in the irbesartan group by 13. 3±８. 7 mmHg and in valsartan group by 16.５± 9. 3 mmHg. Efficacy was achieved in 76. 0% of patients in irbesartan group and 84. 0% in valsartan group (p> 0. 05). The blood pressure was controlled at starting dose in 72. 0% for patients in irbesartan group and 68. 0% in valsartan group (p>0. 05). Adverse reactions were infrequent in both groups. Conclusions：Irbesartan was effective,safe,reliable and well-tolerated in the treatment of mild to moderate essential hypertension.
出处
《中国循环杂志》
CSCD
北大核心
2001年第2期97-99,共3页
Chinese Circulation Journal
